ADIPOQ and prostate carcinoma: There was also weak evidence of a small inverse association of adiponectin with overall prostate cancer (OR 0.96, 95%CI 0.93–0.99, per 2.5 μg/ml increase), but less evidence of an association with aggressive disease (OR 0.98, 95%CI 0.94–1.01).